RESUMO
CaCl2 and aconitic models of arrhythmias were reproduced in experiments with rats. Sodium salicylate was found to decrease the preventive effect of ecetylnovocainamidum and increased the effect of novocainamidum on ECG changes. Sodium salicylate diminished the preventive effect of acetyl-novocainamidum by elevating myocardial Na+ concentrations, favoured the decrease in myocardial K+ levels, eliminated the preventive effects of novocainamide and acetylnovocainamide by altering myocardial energy metabolism in CaCl2-induced arrhythmia and improved the preventive effect of acetyl-novocainamide on these parameters in aconitic arrhythmia.
Assuntos
Acecainida/uso terapêutico , Fenobarbital/uso terapêutico , Procainamida/uso terapêutico , Salicilato de Sódio/uso terapêutico , Aconitina , Animais , Arritmias Cardíacas/sangue , Arritmias Cardíacas/induzido quimicamente , Arritmias Cardíacas/tratamento farmacológico , Arritmias Cardíacas/fisiopatologia , Cloreto de Cálcio , Avaliação Pré-Clínica de Medicamentos , Interações Medicamentosas , Quimioterapia Combinada , Eletrocardiografia/efeitos dos fármacos , Feminino , Masculino , Ratos , Ratos WistarRESUMO
The effects of potassium malate and sodium succinate on the antiarrhythmic activity of novocainamide and acetylnovocainamide during modelling of chlor-calcium-induced arrhythmia as well as in disorders of cardiac rhythm during modelling of pituitrin-isadrine-induced myocardial infarction were studied. The metabolic agents were found to increase the effectiveness of acetylnovocainamide and the toxicity of novocainamide. To interpret the specific features of the mechanism of the anti-arrhythmic action of the compounds there was studied their ability to form complexes with components of biomembranes and ions of biometals.
Assuntos
Antiarrítmicos/uso terapêutico , Malatos/uso terapêutico , Procainamida/análogos & derivados , Procainamida/uso terapêutico , Succinatos/uso terapêutico , Animais , Antiarrítmicos/toxicidade , Arritmias Cardíacas/induzido quimicamente , Arritmias Cardíacas/tratamento farmacológico , Cloreto de Cálcio , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Quimioterapia Combinada , Isoproterenol , Dose Letal Mediana , Infarto do Miocárdio/induzido quimicamente , Infarto do Miocárdio/tratamento farmacológico , Hormônios Neuro-Hipofisários , Potássio/uso terapêutico , Procainamida/toxicidade , Ratos , Ratos Endogâmicos , Ácido SuccínicoAssuntos
Doença das Coronárias/tratamento farmacológico , Digoxina/uso terapêutico , Nucleotídeos de Adenina/metabolismo , Animais , Doença das Coronárias/metabolismo , Avaliação Pré-Clínica de Medicamentos , Complexo IV da Cadeia de Transporte de Elétrons/metabolismo , Miocárdio/metabolismo , RatosRESUMO
Acute teste staged on rats showed low doses of the cardiac glycoside isolanide to bring down the level of total lipids, cholesterol and beta-lipoproteins, without causing any changes in the content of NAD, adenyl nucleotides, non-esterified fatty acids (NEFA) and of phospholipids in themyocardium. Large doses of the drug uniformly reduce the content of all the co-enzymes fractions, the amount of ARP, ADP, cholesterol, beta-lipoproteins and the raise the level of total lipids, phospholipids and NEFA. In cases of acute cardiac insufficiency the drug produces a normalizing action on the co-enzymes and adenyl nucleotides content and reduces that of beta-lipoproteins and cholesterol. It appears that a definite part in the mechanism of the isolanide action plays its influence on the level of nucotinamide co-enzymes, adenyl nucleotides and lipids.